ClinicalTrials.gg
Not yet recruitingNCT07862972Updated Oct 7, 2026

Cryoballoon Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation

An observational study in Paroxysmal Atrial Fibrillation (PAF), sponsored by Shenyang Northern Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Shenyang Northern Hospital · Observational

How we know

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 377 studies in Atrial Fibrillation with a site in China — 162 open to participants now, 183 under way, 4 of them phase 3. Atrial Fibrillation · China.

Planned enrollment
111th of 121
50 · median 500
Started
2026
with 47 others
Observational
121 of 377
48 open now
Primary completion
2027-06
later than 111 of 182 live
Registered
374th of 377
by date

Among the 377 studies in Atrial Fibrillation with a site in China, this one is the 111th largest by planned enrollment of the 121 observational ones that give a count, is one of 48 that started in 2026, is one of 121 observational ones, reaches primary completion later than 111 of the 182 other live ones, and was the 374th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

162 of the 377 studies in Atrial Fibrillation with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Atrial Fibrillation with a site in China, or all of them as a file.
02

Study summary

This post-marketing, multi-center, prospective, single-arm, observational study will be conducted across 3 clinical sites in China and enroll no more than 50 patients with paroxysmal atrial fibrillation. After clinical site initiation, each study site was permitted to enroll up to 2 roll-in cases to allow operators to familiarize themselves with the Nordica® cryoballoon and standardize procedural techniques. A competitive enrollment method will be adopted to recruit up to 50 patients with paroxysmal atrial fibrillation. The Nordica® cryoballoon will be employed for pulmonary vein isolation during the procedure. A 6-month follow-up assessment is scheduled at the following time points: the index hospitalization period (days 0-3), and post-procedure follow-up time points at 30 days, 3 months, and 6 months.

Read the detailed description

Cryoballoon ablation has become an initial therapy for patients with paroxysmal atrial fibrillation, owing to its advantages of procedural standardization, high intraoperative comfort, reliable pulmonary vein isolation, and favorable safety profile. The Nordica® balloon features a single-layer design, offering superior compliance compared to double-layer balloons. This facilitates transmural pulmonary vein isolation (PVI) and reduces the likelihood of segmental ablation and adjacent tissue injury. The balloon maintains an internal pressure of 3 psi or 5 psi with high leak resistance, a design that prevents displacement caused by sudden pressure spikes during ablation and minimizes failures in pulmonary vein isolation due to inadequate contact. Furthermore, the compliant design of the Nordica® balloon conforms better to pulmonary vein anatomy, enabling easy occlusion of the pulmonary veins without the need for additional pushing force. It has been approved for pulmonary vein isolation in this patient population. Previous studies have demonstrated the safety and efficacy of the Nordica® cryoballoon in the treatment of paroxysmal atrial fibrillation. Nevertheless, there is still a lack of multi-center, prospective real-world evidence on the long-term effectiveness, safety, procedural efficiency, and health economic value of the Nordica® cryoballoon in routine clinical practice Therefore, we aim to conduct a multi-center, prospective, single-arm, observational real-world study to assess the post-marketing safety, effectiveness, procedural efficiency, and health economic outcomes of the Nordica® cryoballoon for pulmonary vein isolation in patients with paroxysmal atrial fibrillation, with the goal of developing high-quality, evidence-based guidelines to inform its standardized use in clinical practice.

03

Conditions studied

  • Paroxysmal Atrial Fibrillation (PAF)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients (aged 18-75 years) was documented paroxysmal atrial fibrillation (PAF), eligible for AF catheter ablation, and scheduled to undergo a cryoballoon-based pulmonary vein isolation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-75 years.
  2. Documented paroxysmal atrial fibrillation (PAF), eligible for AF catheter ablation, and scheduled to undergo a cryoballoon-based pulmonary vein isolation.
  3. Willing and able to complete all protocol-required study visits and assessments.
  4. Ability to understand the study procedures and provide written .

Exclusion criteria

Exclusion Criteria:

  1. Prior AF ablation (catheter-based), left atrial maze procedure, or any other pulmonary vein/left atrial intervention;
  2. Left atrial (LA) diameter >55 mm, or severe valvular heart disease requiring surgical intervention;
  3. \< 40%;
  4. Stroke, (TIA), acute coronary syndrome (ACS), Myocardial infarction (MI), Any cardiac surgical or percutaneous cardiac procedure within the last three months;
  5. Left atrial/left atrial appendage thrombus;
  6. Severe liver and/or renal insufficiency;
  7. With bleeding tendency, for anticoagulation, or inability to tolerate oral anticoagulant therapy.
  8. Pregnant or breastfeeding women;
  9. with cryoglobulinemia;
  10. reactions to contrast media;
  11. Any factor that, in the investigator's judgment, renders the patient unsuitable for participation (such as mental illness, or inability to complete follow-up, etc.).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • AF catheter ablation
06

What researchers measure

Primary outcomes

  1. Composite endpoint of 30-day postoperative complications

    Including any of the following adverse events: 1. Death (including all-cause mortality and cardiovascular death); 2. Stroke/ transient ischemic attack; 3. Pericardial tamponade / Pericardial Effusion (need drainage or surgical removal); 4. major vascular complications / major bleeding events (resulting in death, blood transfusion, prolonged hospitalization, or surgical/interventional treatment); 5) major vascular complications (requires repair, intervention, or blood transfusion); 6) Symptomatic pulmonary vein stenosis (requires intervention/ surgery); 7) atrioesophageal fistula/ esophageal injury; 8)persistent phrenic nerve injury (persisting beyond 7 days following the index procedure); 9)Severe arrhythmia (requires cardioversion/emergency drug treatment)

    Time frame: Within 30 days postoperatively

  2. Incidence of freedom from atrial arrhythmia at 6 months postoperatively

    Defined as the proportion of subjects free from any documented atrial tachyarrhythmia - including atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL) lasting ≥30 seconds - occurring. These episodes must be confirmed by 12-lead electrocardiogram (ECG) and seven-day Holter monitoring following a 6-month period post-ablation.

    Time frame: At 6 months postoperatively

Secondary outcomes

  1. Acute success rate of pulmonary vein isolation

    Defined as the proportion of subjects with confirmed complete isolation of all pulmonary veins.

    Time frame: Intraoperative

  2. The extended major safety endpoints, minor adverse events, and other medical device adverse event or procedure-related adverse event

    1. Transient phrenic nerve palsy (requiring brief intervention therapy, recovered prior to discharge); 2. Minor vascular access complications (without intervention/ surgery); 3. Minor bleeding (without transfusion, surgical/interventional treatment); 4. Asymptomatic pulmonary vein stenosis (without intervention); 5. Non-serious cardiovascular and pulmonary medical device and/or procedure-related adverse events; 6. medical device related adverse events (e.g., mild vascular irritation related to catheter manipulation; device performance anomaly without serious clinical sequelae)

    Time frame: Intraoperative/within 30 days postoperatively/at 6 months postoperatively

  3. Procedure efficiency

    Will be described using (mean, median, and distribution): total procedure room time, procedure time, pulmonary vein isolation time, left atrial dwell time, the length of hospital stay (LOS), ablation time, the number of ablation applications, time to isolation (TTI), and fluoroscopy time, fluoroscopy dose.

    Time frame: Intraoperative

  4. Health economics

    Will be described using (mean and distribution): direct medical costs of subjects (procedure cost, device cost, examination costs, medication costs, hospitalization costs, etc.).

    Time frame: From enrollment to the end of treatment at 6 months postoperatively

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jun 2027, 8 months later.

Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 8 months is below that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 7, 2026
StartEst.
Oct 15, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Oct 30, 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07862972
Lead sponsor
Shenyang Northern Hospital
Collaborators
Tianjin Chest Hospital, The First Hospital of Jilin University
Responsible party
Han Yaling (Prof., Shenyang Northern Hospital) — Principal investigator
First posted
Oct 7, 2026
Start date
Oct 15, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Yaling Han
Contact
cardiology@163.com
86-24-23922184
Zulu Wang
Contact
wangzulu62@126.com
86-24-23922184

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion